Targeting the CaN/FoxO1/FABP4 Pathway in SERCA2 Dysfunction: Implications for Foam Cell Formation and Atherosclerosis

Study Background and Research Question

Atherosclerosis, a chronic vascular disease, is characterized by lipid-laden foam cell accumulation and inflammatory plaque development in arterial walls. The progression of atherosclerosis is driven by complex interactions among lipid metabolism, immune signaling, and vascular cell function. One underexplored molecular contributor is sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2), specifically its cysteine 674 (C674) residue, which maintains Ca²⁺ homeostasis and prevents endoplasmic reticulum (ER) stress. Disruption of SERCA2, such as through the C674S mutation, has been linked to exacerbated inflammation and lipid accumulation, but the mechanistic pathways connecting SERCA2 dysfunction to atherosclerotic lesion formation remain insufficiently defined (paper). This study addresses whether SERCA2 dysfunction aggravates atherosclerosis by promoting macrophage foam cell formation through dysregulation of fatty acid metabolism, and whether targeting the downstream calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid-binding protein 4 (FABP4) axis can prevent these pathogenic changes.

Key Innovation from the Reference Study

The central innovation lies in elucidating a direct mechanistic pathway linking SERCA2 dysfunction to foam cell formation and atherosclerosis progression via the CaN/FoxO1/FABP4 axis. The authors demonstrate that loss-of-function in SERCA2 triggers calcineurin activation, promoting nuclear translocation of FoxO1 and upregulation of its downstream target, FABP4. Increased FABP4 expression in macrophages facilitates aberrant fatty acid uptake and esterification, fostering lipid droplet accumulation and foam cell phenotype. Importantly, the work provides evidence that pharmacological inhibition or genetic reduction of FABP4 effectively interrupts this pathogenic cascade, highlighting FABP4 as a tractable target for atherosclerosis intervention (paper).

Methods and Experimental Design Insights

The investigators employed a multifaceted in vivo and in vitro approach. Heterozygous SERCA2 C674S knock-in (SKI) mice were generated to model SERCA2 dysfunction under pathological conditions. Aortic tissues from SKI and wild-type littermates were harvested for histological and lipidomics analysis, while bone marrow-derived macrophages (BMDMs) were isolated for mechanistic studies. Key experimental components included:

• Histological quantification of atherosclerotic lesions and foam cell content in the aorta and aortic root.
• Metabolomic profiling of serum samples to assess systemic lipid alterations.
• Western blotting and immunofluorescence to analyze protein expression and nuclear translocation (e.g., FoxO1, FABP4).
• Genetic and pharmacological interventions targeting FoxO1 (AS1842856) and FABP4 (BMS 309403), as well as analysis of FABP4 partial knockout mice.
• Functional readouts including lipid uptake, esterification, and foam cell formation in BMDMs.

Protocol Parameters

• assay | BMS 309403 concentration | 1–25 μM | In vitro inhibition of FABP4 in BMDM foam cell assays | workflow_recommendation
• assay | Chronic BMS 309403 dosing in ApoE^-/- mice | 15 mg/kg/day (i.p.) | In vivo atherosclerosis progression studies | product_spec
• assay | DMSO as vehicle for BMS 309403 | ≥18.15 mg/mL solubility | Ensures adequate compound dissolution for cell-based assays | product_spec
• assay | FABP4 expression quantification via Western blot | Standardized signal normalization | Monitors target engagement and pathway modulation | paper
• assay | Histological quantification of atherosclerotic lesion area | Oil Red O staining | Measures foam cell and lipid accumulation | paper

Core Findings and Why They Matter

The study's principal findings are as follows:

• SERCA2 C674S mutation in mice induces ER stress and markedly increases atherosclerotic lesion size and foam cell content in the aorta compared to wild-type controls (paper).
• In BMDMs from SKI mice, SERCA2 deficiency upregulates calcineurin, which in turn promotes FoxO1 nuclear localization and transcriptional activation of FABP4.
• Elevated FABP4 expression heightens fatty acid uptake, lipid droplet formation, and foam cell phenotype—key contributors to plaque progression.
• Pharmacological inhibition of FoxO1 or FABP4, or partial genetic deficiency of FABP4, significantly reduces foam cell formation and atherosclerotic lesion burden.
• Targeting the CaN/FoxO1/FABP4 pathway normalizes lipid metabolism, indicating a critical axis for therapeutic intervention.

These results clarify a previously uncharacterized mechanism by which SERCA2 dysfunction drives atherogenesis, placing FABP4 at the center of a pathogenic metabolic-inflammation axis. The demonstration that a potent FABP4 inhibitor can reverse these effects provides strong preclinical evidence for the utility of this target in cardiovascular disease models (paper).

Comparison with Existing Internal Articles

Several internal resources further contextualize and complement these findings:

• Inhibiting FoxO1/FABP4 Pathway Prevents SERCA2-Induced Atherosclerosis expands on the reference study, describing how targeting the FoxO1/FABP4 branch corrects lipid metabolism and supports the use of selective FABP4 inhibitors in advanced cardiovascular models.
• BMS 309403: FABP4 Inhibitor Workflows for Atherosclerosis Research offers practical guidance on experimental design and troubleshooting for researchers aiming to dissect the calcineurin/FoxO1/FABP4 axis, with detailed workflows for in vitro and in vivo studies.
• BMS 309403: Precision Modulation of FABP4 in Lipid Metabolism Research provides additional mechanistic detail on the role of FABP4 in inflammation and lipid handling, which is directly relevant to the current study’s findings regarding foam cell formation.

Together, these resources reinforce the centrality of FABP4 in atherogenic processes and highlight BMS 309403 as a key tool compound for dissecting lipid-inflammation crosstalk in cardiovascular research.

Limitations and Transferability

While the study robustly demonstrates that pharmacological and genetic targeting of FABP4 mitigates SERCA2 dysfunction-induced atherosclerosis in mouse models and primary macrophages, several limitations must be considered:

• Findings are derived from genetically engineered mouse models (SKI and FABP4^+/-), which may not fully recapitulate human disease complexity.
• Off-target effects of pharmacological inhibitors, including BMS 309403, though reportedly minimal due to high selectivity (Ki < 2 nM), require careful validation in translational studies (product_spec).
• Long-term effects and safety of chronic FABP4 inhibition in diverse metabolic contexts have yet to be fully elucidated.
• Transferability to other inflammatory or metabolic diseases should be approached with caution unless supported by direct pathway evidence (paper).

Research Support Resources

Researchers interested in probing the role of FABP4 in atherosclerosis, metabolic disease, or inflammation can leverage selective inhibitors such as BMS 309403 (SKU B7794), a well-characterized, DMSO-soluble FABP4 inhibitor with documented utility in both cell-based and animal models (product_spec). For experimental protocols, including optimal concentrations and storage guidelines, refer to workflow recommendations and detailed product specifications. APExBIO provides BMS 309403 for research use, facilitating precise modulation of FABP4 in lipid metabolism and atherosclerosis studies. For stepwise protocols and additional assay design guidance, consult internal resources on advanced FABP4 inhibition workflows.